| Back to main Menu |
| Back to Clinical |
G6760 Cerebral infarction due to cerebral venous thrombosis, nonpyogenic
bu5..%
Long-term antiplatelet therapy reduces the risk of serious vascular events following a stroke by about a quarter. Antiplatelet therapy, normally aspirin, should be prescribed for the secondary prevention of recurrent stroke and other vascular events in patients who have sustained an ischaemic cerebrovascular event.
Grade A recommendation SIGN 108 (2008)
Further information: www.sign.ac.uk/guidelines/fulltext/108/index.html
All patients who are not anti-coagulated should be taking aspirin (50–300mg) daily, or a combination of low-dose aspirin and dipyridamole modified release (MR). Where patients are aspirin-intolerant an alternative antiplatelet agent (clopidogrel 75mg daily) should be used.
Grade A Recommendation RCP Stroke Guideline
http://bookshop.rcplondon.ac.uk/details.aspx?e=250
Further information:
The National Clinical Guideline for Stroke (Royal College of Physicians of
London, 2004) now allows for the use of dipyridamole on its own: ‘all
patients with ischaemic stroke or TIA who are not on anticoagulation, should
be taking an antiplatelet agent, i.e. aspirin (50–300mg daily), clopidogrel,
or a combination of low-dose aspirin and dipyridamole modified release. Where
patients are aspirin intolerant an alternative antiplatelet agent (e.g. clopidogrel
75mg daily or dipyridamole MR 200mg twice daily) should be used.’
Warfarin should be considered for use in patients with non-valvular atrial fibrillation.
The practice reports the percentage of patients with non-haemorrhagic stroke or TIA who have a record in the preceding 15 months of prescribed aspirin, clopidogrel, dipyridamole MR or warfarin, or of taking over the counter aspirin updated in the preceding 15 months.
Prepared By Jean Keenan